Suppr超能文献

重复细胞减灭术-腹腔内热灌注化疗在选择的腹膜转移患者中是可行的,并提供生存获益。

Repeat Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemoperfusion is Feasible and Offers Survival Benefit in Select Patients with Peritoneal Metastases.

机构信息

Division of Surgical Oncology, Koch Regional Perfusion Center, University of Pittsburgh, Pittsburgh, PA, USA.

The University of Pittsburgh Cancer Institute Biostatistics Facility, Pittsburgh, PA, USA.

出版信息

Ann Surg Oncol. 2019 May;26(5):1445-1453. doi: 10.1245/s10434-019-07218-w. Epub 2019 Mar 1.

Abstract

INTRODUCTION

We hypothesized that repeat cytoreductive surgery-hyperthermic intraperitoneal chemoperfusion (CRS-HIPEC) for peritoneal metastases (PM) may be associated with suboptimal resection, more frequent postoperative complications, and worse oncologic outcomes.

METHODS

Using a prospectively maintained database, we compared clinicopathologic, perioperative, and oncologic outcome data in patients undergoing single or repeat CRS-HIPEC procedures. The Kaplan-Meier method was used to estimate survival. Multivariate analyses identified associations with perioperative and oncologic outcomes.

RESULTS

Of the 1294 patients undergoing CRS-HIPEC procedures at our institution, only one CRS-HIPEC procedure (single HIPEC cohort) was performed in 1169 patients (90.3%), whereas 125 patients (9.7%) underwent repeat CRS-HIPEC procedures (repeat HIPEC cohort). Of the 1440 CRS-HIPEC procedures at our institution, a first CRS-HIPEC procedure was performed in 1294 patients (89.9%), whereas subsequent second, third, and fourth CRS-HIPEC procedures were performed in 125 patients (8.7%), 18 patients (1.3%), and 3 patients (0.2%), respectively. Progression-free survival (PFS) following the second CRS-HIPEC procedure was negatively impacted by shorter PFS following the first CRS-HIPEC procedure, independent of other significant variables related to the second procedure, including completeness of cytoreduction and postoperative complications. Patients undergoing multiple CRS-HIPEC procedures were not at higher risk for suboptimal resection or postoperative complications and demonstrated equivalent PFS following each successive procedure compared to the first procedure.

CONCLUSIONS

Repeat CRS-HIPEC procedures for PM were not associated with suboptimal perioperative and oncologic outcomes. Our data confirmed our ability to select patients appropriately for repeat CRS-HIPEC procedures.

摘要

引言

我们假设对于腹膜转移(PM)的重复细胞减灭术-腹腔内热灌注化疗(CRS-HIPEC)可能与不充分的切除、更频繁的术后并发症和更差的肿瘤学结果相关。

方法

我们使用前瞻性维护的数据库,比较了接受单次或重复 CRS-HIPEC 手术的患者的临床病理、围手术期和肿瘤学结局数据。Kaplan-Meier 方法用于估计生存。多变量分析确定了与围手术期和肿瘤学结局相关的因素。

结果

在我们机构接受 CRS-HIPEC 手术的 1294 名患者中,仅有 1169 名患者(90.3%)接受了单次 CRS-HIPEC 手术(单次 HIPEC 队列),而 125 名患者(9.7%)接受了重复 CRS-HIPEC 手术(重复 HIPEC 队列)。在我们机构的 1440 次 CRS-HIPEC 手术中,1294 名患者(89.9%)接受了首次 CRS-HIPEC 手术,而随后的第二次、第三次和第四次 CRS-HIPEC 手术分别在 125 名患者(8.7%)、18 名患者(1.3%)和 3 名患者(0.2%)中进行。第二次 CRS-HIPEC 手术后的无进展生存期(PFS)受到首次 CRS-HIPEC 手术后较短 PFS 的负面影响,这与与第二次手术相关的其他重要变量无关,包括细胞减灭的完整性和术后并发症。接受多次 CRS-HIPEC 手术的患者并没有更高的风险出现不充分切除或术后并发症,并且与首次手术相比,在随后的每次手术中都表现出等效的 PFS。

结论

PM 的重复 CRS-HIPEC 手术与围手术期和肿瘤学结果不佳无关。我们的数据证实了我们能够适当地选择接受重复 CRS-HIPEC 手术的患者。

相似文献

引用本文的文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验